Harnessing intermediate-scale bioreactors for next-generation macrophage production and application

Area of Science:

• Immunology
• Stem Cell Biology
• Biotechnology

Background:

• Macrophages are vital immune cells with broad therapeutic potential.
• Induced pluripotent stem cell (iPS cell)-derived macrophages offer promise for regenerative medicine and disease treatment.
• Current limitations exist in cost-effective, standardized intermediate-scale bioreactor systems for academic research.

Purpose of the Study:

• To present a user-friendly, feeder-free, semi-defined protocol for standardized iPS cell-derived macrophage production.
• To enable intermediate-scale (10-50 mL) bioreactor manufacturing of macrophages for early-stage research and drug discovery.
• To provide a scalable and reproducible method for generating human immune cells.

Main Methods:

• Extension of a previously published protocol using a benchtop bioreactor system.
• Generation of mesoderm-primed aggregates (hemanoids) with hematopoietic potential.
• Semi-automated platform with in-process monitoring of critical parameters (CO2, temperature, pH).

Main Results:

• Standardized production of iPS cell-derived macrophages from single-cell iPS cells in 24 days.
• Continuous macrophage generation over a minimum of five consecutive collections.
• Average yield of 2-3 × 10^7 cells per collection per vessel, with high reproducibility and cell quality.

Conclusions:

• The protocol provides a scalable and standardized method for producing iPS cell-derived macrophages.
• This approach bridges the gap between small- and large-scale systems, benefiting academic research.
• The user-friendly, semi-automated platform enhances process control and cell quality for immune cell studies.